Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Millan

Showing results (31-40 of 188) with videos related to

Pageof 19
Sort By:
Psychopharmacology|August 19, 2007
Evaluation of serotonin, noradrenaline and dopamine reuptake inhibitors on light-induced phase advances in hamster circadian activity rhythmsRobert L Gannon, Mark J Millan
European Journal of Pharmacology|November 26, 2005
The selective tachykinin neurokinin 1 (NK1) receptor antagonist, GR 205,171, stereospecifically inhibits light-induced phase advances of hamster circadian activity rhythmsRobert L Gannon, Mark J Millan
Psychopharmacology|April 2, 2014
CRF1 receptor-deficiency induces anxiety-like vulnerability to cocaineNadège Morisot, Mark J Millan, Angelo Contarino
Brain Research|June 14, 2002
The selective neurokinin (NK)(1) antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological studyFrançoise Lejeune, Alain Gobert, Mark J Millan
Psychopharmacology|October 9, 2007
Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortexFlorence Loiseau, Anne Dekeyne, Mark J Millan
The International Journal of Neuropsychopharmacology|July 8, 2011
Molecular adaptation to chronic antidepressant treatment: evidence for a more rapid response to the novel α₂-adrenoceptor antagonist/5-HT-noradrenaline reuptake inhibitor (SNRI), S35966, compared to the SNRI, venlafaxineFlorence Serres, Mark J Millan, Trevor Sharp
European Journal of Pharmacology|February 6, 2004
Characterisation of Gs activation by dopamine D1 receptors using an antibody capture assay: antagonist properties of clozapineDidier Cussac, Valérie Pasteau, Mark J Millan
Journal of Psychopharmacology (Oxford, England)|October 21, 2016
The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disordersMark J Millan, Jean-Michel Rivet, Alain Gobert
Behavioural Pharmacology|October 6, 2006
Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptorsMauricette Brocco, Anne Dekeyne, Mariusz Papp, et al.
Neuropharmacology|September 8, 2009
The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned ratsFlora Mela, Mark J Millan, Mauricette Brocco, et al.
Pageof 19

Showing results (31-40 of 188) with videos related to

Sort By:
Pageof 19
Psychopharmacology|August 19, 2007
Evaluation of serotonin, noradrenaline and dopamine reuptake inhibitors on light-induced phase advances in hamster circadian activity rhythmsRobert L Gannon, Mark J Millan
European Journal of Pharmacology|November 26, 2005
The selective tachykinin neurokinin 1 (NK1) receptor antagonist, GR 205,171, stereospecifically inhibits light-induced phase advances of hamster circadian activity rhythmsRobert L Gannon, Mark J Millan
Psychopharmacology|April 2, 2014
CRF1 receptor-deficiency induces anxiety-like vulnerability to cocaineNadège Morisot, Mark J Millan, Angelo Contarino
Brain Research|June 14, 2002
The selective neurokinin (NK)(1) antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological studyFrançoise Lejeune, Alain Gobert, Mark J Millan
Psychopharmacology|October 9, 2007
Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortexFlorence Loiseau, Anne Dekeyne, Mark J Millan
The International Journal of Neuropsychopharmacology|July 8, 2011
Molecular adaptation to chronic antidepressant treatment: evidence for a more rapid response to the novel α₂-adrenoceptor antagonist/5-HT-noradrenaline reuptake inhibitor (SNRI), S35966, compared to the SNRI, venlafaxineFlorence Serres, Mark J Millan, Trevor Sharp
European Journal of Pharmacology|February 6, 2004
Characterisation of Gs activation by dopamine D1 receptors using an antibody capture assay: antagonist properties of clozapineDidier Cussac, Valérie Pasteau, Mark J Millan
Journal of Psychopharmacology (Oxford, England)|October 21, 2016
The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disordersMark J Millan, Jean-Michel Rivet, Alain Gobert
Behavioural Pharmacology|October 6, 2006
Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptorsMauricette Brocco, Anne Dekeyne, Mariusz Papp, et al.
Neuropharmacology|September 8, 2009
The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned ratsFlora Mela, Mark J Millan, Mauricette Brocco, et al.
Pageof 19